Want to see AU:EXL full AI Analyst Report?
EXL Stock Chart & Stats
AU$0.02
<AU$0.01(16.67%)
At close: 4:00 PM EDT
AU$0.02
<AU$0.01(16.67%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume100.00K
Average Volume (3M)5.59M
Market Cap
AU$3.18M
Enterprise ValueAU$5.52M
Total Cash (Recent Filing)AU$996.00K
Total Debt (Recent Filing)AU$4.03M
Price to Earnings (P/E)―
Beta-1.24
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding454,112,180
10 Day Avg. Volume15,329,612
30 Day Avg. Volume5,590,708
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.15
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryRevenue has recovered materially from the 2022–2023 base, indicating that the company retains demand for its branded hemp and CBD wellness products. Although 2025 growth turned negative, the higher revenue platform may support future operating improvement if the business can restore margins and control costs.
Historically Moderate LeverageHistorically moderate debt-to-equity suggests the company had some balance-sheet capacity relative to its equity base before the 2025 deterioration. This provides a stronger starting position than a highly leveraged structure, although preserving that flexibility depends on reducing losses and avoiding further debt increases.
Improving Cash BurnThe direction of cash generation has improved from the much heavier burn recorded in 2020–2022, while 2025 free cash flow was better than in 2024. This suggests some progress in financial control, creating a potential foundation for stronger funding capacity if operations eventually reach positive cash generation.
Bears Say
Persistent LossesRecurring negative EBIT and net income show that the business has not yet demonstrated durable profitability across the reported period. Continued losses reduce retained capital, limit internally funded investment, and make the company more dependent on operational improvement or external financing to sustain its strategy.
Severe Margin PressureThe sharp fall in gross profit despite the recovery in revenue indicates substantial pressure on product economics and margin sustainability. If this deterioration persists, higher sales may not translate into improved earnings, weakening the scalability of the branded wellness and CBD business model.
Negative Cash GenerationConsistently negative operating and free cash flow means the company has not shown an ability to fund operations internally. Ongoing cash burn increases reliance on financing while losses persist, reducing strategic flexibility and making balance-sheet resilience more important over the next several quarters.
Elixinol Wellness News
EXL FAQ
What was Elixinol Wellness’s price range in the past 12 months?
Elixinol Wellness lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Elixinol Wellness’s market cap?
Elixinol Wellness’s market cap is AU$3.18M.
When is Elixinol Wellness’s upcoming earnings report date?
Elixinol Wellness’s upcoming earnings report date is Feb 19, 2027 which is in 113 days.
How were Elixinol Wellness’s earnings last quarter?
Elixinol Wellness released its earnings results on Aug 31, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is Elixinol Wellness overvalued?
According to Wall Street analysts Elixinol Wellness’s price is currently Overvalued.
Does Elixinol Wellness pay dividends?
Elixinol Wellness does not currently pay dividends.
What is Elixinol Wellness’s EPS estimate?
Elixinol Wellness’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elixinol Wellness have?
Elixinol Wellness has 454,112,180 shares outstanding.
What happened to Elixinol Wellness’s price movement after its last earnings report?
Elixinol Wellness reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elixinol Wellness?
Currently, no hedge funds are holding shares in AU:EXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elixinol Wellness Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EXL Sentiment 60%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-50.35%
Trailing 12-Months
Asset Growth
-3.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elixinol Wellness
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp-derived products, encompassing nutraceuticals, cosmetics, and various food items. These products are marketed under its distinct brands, Elixinol and Hemp Foods Australia, reaching consumers across the Americas, Europe, and Australia. Its extensive product range features hemp-derived cannabidiol (CBD) items, food products, dietary supplements, and topical skincare solutions. Notably, the company transitioned to its current name in May 2021, having previously been known as Elixinol Global Limited.
Technical Analysis
Cann Group
―
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―